close
Add to watchlist
Cardiome Pharma Corp (CRME) Healthcare, Biotechnology & Drugs
Cardiome Pharma Corp., a life sciences company, focuses on developing drugs to treat or prevent cardiovascular diseases. Its product Vernakalant (iv), which has completed Phase III (ACT 4) and in Phase III (European Comparator) trial is used for the treatment of atrial fibrillation; Vernakalant (oral) that has completed Phase IIa Pilot and Phase IIb study is used for atrial fibrillation; GED-aPC, an ongoing Phase I study product for multiple disease states; and Artesian Programs, which is in pre-clinical studies to attenuate the deleterious effects of the excessive neurohormonal activation that occurs in diseases of cardiac dysfunction. The company was formerly known as Nortran Pharmaceuticals, Inc. and changed its name to Cardiome Pharma Corp. in 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 1.96 |
| Volume | 210002 |
| Volume Avg | 188574 |
| 52 Week High | 5.86 |
| 52 Week Low | 1.86 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.48 |
| EPS change Q/Q | 0% |
| EPS change Q/Q Yr ago | 1000% |
| EPS change Q/Q next Q est | -9.09% |
| EPS change Y/Y | 100% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | -98.26% |
| EPS next Q est | -0.11 |
| EPS next Y est | -0.21 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |